For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has AEterna Zentaris (AEZS) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
AEterna Zentaris is a member of the Medical sector. This group includes 839 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. AEZS is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for AEZS's full-year earnings has moved 708.11% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, AEZS has returned 30.95% so far this year. Meanwhile, stocks in the Medical group have gained about 2.64% on average. As we can see, AEterna Zentaris is performing better than its sector in the calendar year.
Breaking things down more, AEZS is a member of the Medical - Biomedical and Genetics industry, which includes 345 individual companies and currently sits at #58 in the Zacks Industry Rank. This group has gained an average of 8.89% so far this year, so AEZS is performing better in this area.
Going forward, investors interested in Medical stocks should continue to pay close attention to AEZS as it looks to continue its solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AEterna Zentaris Inc. (AEZS) : Free Stock Analysis Report
To read this article on Zacks.com click here.